Ranga Sarangarajan, Ph.D
Senior Vice President & Chief Scientific Officer

ranga_s_cropped

Dr. Sarangarajan is the Senior Vice President & Chief Scientific Officer at BERG oversees all research & development activities. He is the co-inventor and co-architect of the BERG Interrogative Biology® technology and leads the implementation of scientific strategies and overall operations of the multifunctional integrated scientific program intersecting science and technology. He is responsible for developing strategies for rapid validation of preclinical and translation into clinical development and beyond of drug targets, therapeutics and biomarkers in the areas of cancer, cardiovascular and metabolic diseases, neurological diseases and other area(s) of BERG focus.

Dr. Sarangarajan’s education as a pharmacist and his diversity in graduate training provided the scientific acumen and knowledge base for diligent implementation of the fundamental tenets underlying the BERG Interrogative Biology® platform and the appropriate translation of its outputs in creation of the diverse BERG program pipeline. At the Massachusetts College of Pharmacy and Health Sciences (MCPHS), he oversaw the implementation of an integrated biological sciences program that intersected the basic sciences to clinical outcomes within the pharmacy curriculum. The transition to BERG provided Dr. Sarangarajan the opportunity to translate the concepts of study of integrating biological systems to drug discovery and development.

Dr. Sarangarajan has numerous US and international pending patent applications, covering areas of discovery platform, cancer, metabolic diseases, diabetes, obesity and diagnostics. He has published extensively and has presented his research in national and international medical and scientific meetings. He co-authored and co-edited Cellular Respiration and Carcinogenesis, a first of its kind treatise on the role of mitochondrial function and metabolic network regulation in the etiology of cancer as it pertains to the seminal observations made by Otto Warburg. Dr. Sarangarajan is a member of numerous professional organizations and has served in various capacities including the New England Society of Cosmetic Chemists, the Society of Toxicology, American Society for Pharmacology & Experimental Therapeutics, American Association of Colleges of Pharmacy and has been a reviewer for many scientific journals in the areas of pharmacology & toxicology. Dr. Sarangarajan received his B.S. in Pharmacy from Maharaja Sayajirao University (India) and a Ph.D. in Pharmaceutical Sciences from the University of Cincinnati College of Pharmacy. He received post-doctoral training at the University of Cincinnati Children’s Hospital Research Foundation and Department of Dermatology prior to moving to MCPHS.